Doctors Who Treat Respiratory Problems in Neurologically Impaired Children | NYU Langone Health
View a list of doctors who treat Respiratory Problems in Neurologically Impaired Children at Hassenfeld Children’s Hospital at NYU Langone.
Childhood Cancers & Blood Disorders We Treat | NYU Langone Health
At NYU Langone’s Stephen D. Hassenfeld Children’s Center for Cancer and Blood Disorders, we provide expert treatment for many conditions.
Types of Birthmarks in Children | NYU Langone Health
Doctors at Hassenfeld Children’s Hospital of New York identify birthmarks, including hemangiomas, salmon patches, port wine stains, and moles.
CBYL719F12201: EPIK-P2 Phase II double-blind study w/ upfront 16-week randomized placebo-controlled period to assess efficacy safety & pharmacokinetics of alpelisib (BYL719) in pediatric & adult patients w/ PIK3CA-related overgrowth spectrum (PROS)
This study will be the first prospective study of alpelisib in participants with PROS. Local overgrowth or hemihypertrophy, mostly progressive, is the most frequently observed manifestation of the disease, often causing functional and/or mobility impairment andreduction in health related quality of life. The first experience with alpelisib in overgrowth related to mutation in PIK3CA gene provides the direct evidence of clinical improvement in participants supporting PIK3CA inhibition as a promising therapeutic strategy in participants with PROS. PROS is a serious condition with no approved pharmacological treatment targeting the underlying cause of the disease. Current therapy includes debulking surgery, amputation, and/or endovascular occlusive procedures and mainly addresses symptoms and complications of the disease. There is a high unmet medical need for an effective systemic treatment.The purpose of this study is to assess the efficacy, safety/tolerability and evaluate pharmacokinetics (PK) of alpelisib in participants of different ages with confirmed diagnosis of PROS. As the disease continues throughout the participant life and may be diagnosed at different time points (Keppler-Noreuil et al 2014), the study will enroll adult participants (Group 1; treated with film-coated tablets (FCT)), 6-17 years old pediatric participants (Group 2; treated with FCT), and two exploratory sets of 2-5 years old pediatric participants (Group 3 treated with granules and Group 4 treated with FCT).Group 3 will be enrolled after the completion of the primary analysis when the efficacy, safety and PK data will be available from the participants in Groups 1 and 2 in addition to the data from Group 4 as available, in order to select the recommended dose forparticipants in Group 3. Recruitment of participants in Group 3 will start only after submission and approval of a Substantial Global Protocol Amendment specific to this group. Group 4 will be enrolled before Group 3 and immediately after implementation of this Global Protocol Amendment 01.
Glaucoma | NYU Langone Health
NYU Langone doctors manage glaucoma, a degenerative eye condition, to slow or stop its progression and preserve vision.
Concussion Center | NYU Langone Health
The expert team at NYU Langone’s Concussion Center provides the medical and rehabilitation support you need to recover from a head injury.
Harkness Center for Dance Injuries | NYU Langone Health
NYU Langone’s Harkness Center for Dance Injuries provides affordable medical and preventive care to dancers.
Doctors Who Treat Cystic Fibrosis in Children | NYU Langone Health
View a list of doctors who treat Cystic Fibrosis in Children at Hassenfeld Children’s Hospital at NYU Langone.
Dr. Mary Pat Gallagher, Director of the Pediatric Diabetes Center | NYU Langone Health
Dr. Mary Pat Gallagher, director of NYU Langone’s Pediatric Diabetes Center, believes it takes a village to support a child with diabetes.
Diagnosing Deep Vein Thrombosis | NYU Langone Health
NYU Langone doctors perform tests to identify deep vein thrombosis, or DVT, a blood clot in the leg that can lead to dangerous complications.